Innovation – A key success factor for Switzerland

Switzerland scores repeated high in innovation indexes. As a small country with little raw material base, it is clear that the economy can only be competitive with sustainable innovation. The Innovation Walls presented at this year’s Biotechnica is a selection in the field of drug development. Various stakeholders from academia to companies play an important role to realise innovation pipeline.

Swiss Biotech Sector 2013

According to definitions of the Organisation for Economic Cooperation and Development (OECD) – which are the basis of the report – there were 197 Swiss companies which used biotechnological methods in at least some of their business units in 2012. The reports shows how the sector was developed and what can be expected in the future. The work was supported by the State Secretariat for Education, Research and Innovation (SERI) of the Swiss Federal Department of Economic Affairs, Education and Research and constitutes a voluntary contribution to the Organization for Economic Cooperation and Development (OECD) and has been executed by Biocom, Berlin.
Participating Companies at Biotechnica 2013

AAC Infotray AG
Mr. Oliver Gruber
Phone +41 52 260 31 31
sales@infotray.com
www.limsophy.com

BioConcept
Dr. Ralph Pfister
Phone +41 61 486 80 80
info@biocconcept.ch
www.biocconcept.ch

Biopôle SA
Mr. Lionel Eperon
Phone +41 21 651 90 00
info@biopole.ch
www.biopole.ch

CSEM SA
Ms. Beatriz Tur
Phone +41 32 720 55 75
btu@csem.ch
www.csem.ch

Enzo Life Sciences (ELS) AG
Ms. Corinna Larbi
Phone +41 61 926 89 89
clarbi@enzolifesciences.com
www.enzolifesciences.com

Genohm
Mr. Frederik Decouttere
Phone +41 79 822 40 62
frederik@genohm.com
www.genohm.com

INOFEA
Mr. Alessandro Cumbo
Phone +41 61 633 30 19
contact@inofea.com
www.inofea.com

Lonza
Münchneinerstrasse 38
4002 Basel
Tel. +41 61 316 81 11
contact@lonza.com
www.lonza.com

Sensile Medical AG
Mr. Daniel Seitz
Phone +41 62 209 71 20
Cell +41 79 752 23 20
daniel.seitz@sensile-medical.com
www.sensile-medical.com

Sias AG
Ms. Clare Dench
Phone +41 55 254 11 22
clare.dench@sias.biz
www.sias.biz

SIX Swiss Exchange
Mrs. Andrea von Bartenwerffer
Sehaustrasse 30
Postfach 1758
8021 Zürich
Phone +41 58 399 2111
www.six-group.com

Soconex Isba S.A.
Ms. Laurence Lovy-Drevici
Phone +41 21 651 60 00
socorex@socorex.com
www.socorex.com

SIX Swiss Exchange
Mrs. Andrea von Bartenwerffer
Sehaustrasse 30
Postfach 1758
8021 Zürich
Phone +41 58 399 2111
www.six-group.com

TPP Techno Plastic Products AG
Ms. Kirsten Braehler
Phone +41 52 687 01 85
kbr@tpp.ch
www.tpp.ch

Volpi AG
Mr. Thomas Trachsler
Phone +41 44 732 43 43
mail@volpi.ch
www.volpi.ch
**Biotechnica – Longtime Participant – BioConcept**

Since the foundation in 1978 BioConcept became a leading supplier and service partner to the biological research community representing a full range of sterile products in cell and tissue culture. Production of customer designed media is the speciality of our activities and one of the main strengths.

Recognising that the rapid advances in cell biology require a service partner offering more than standard catalogue media, we invested in a manufacturing facility for sterile cell culture media to be able to provide customers all over the world with a high quality specialised cell and tissue culture medium portfolio. Our customer service and manufacturing operations are covered by an ISO 9001:2008 certified Quality Management System. The powder production equipment of BioConcept can handle batch sizes up to 700 kg. Beside cell culture media, BioConcept offers equipment for sterile production and filling of petri dishes. ‘BioConcept is recognized as a leading supplier in our activity fields’ notes owner and CEO Martin Howald. He is board member in the Swiss Biotech Association since the start of the association in 1998. ‘Biotechnica is part of our planning since 1995. First, I visited the show to create contacts, since 1999 my company is part of the Swiss Pavilion.’

**Switzerland – Active Partner in the European Biotech Week**

Prior to the Biotechnica week, led by Swiss Biotech™, two regional highlights took place in the Western Part of the country, the Romandie.

**October 3, Renens**

The NTN Inartis, a Network for Life Sciences in Western Switzerland conducted a ½ day event on the subject of “Process Control in the Medtech & Biotech Industry”. Topics varied from control and automation to robotics in this dynamic segment of Life Sciences.

Key speakers from academia and industry covered the various topics. Well over 50 persons enjoyed a standing lunch after the presentations and used the opportunity for networking and one-to-one partnering discussions.

**October 4, Lausanne**

The NTN Swiss Biotech™ highlighted in the first Swiss Biotech Day in Western Switzerland the results of the first ever Swiss OECD survey for biotechnology. Various cases from biotech companies and networks followed and demonstrated innovative ways to accelerate drug development. A comprehensive panel on regional – national and international network potential concluded the successful event with more than 100 participants.

**Biotech meets Medtech**

*Companion diagnostics complement diagnosis and treatment*

The new class of in-vitro diagnostics commonly called ‘companion diagnostics’ influences the diagnostic process. Regulatory considerations follow this complex and interesting new merging field.

The discovery of fundamental molecular disease pathways has allowed the diagnosis of disease bases on underlying mechanisms, as well as the development of medicines targeting specific pathways. These developments change our understanding of disease overall and result in a new disease taxonomy based on molecular disease mechanisms. The new approach to the classification and diagnosis of disease has inspired a new generation of diagnostic tools based on mechanism-specific biomarkers.

**Regulatory concerns can be:**

- If a companion diagnostic was used during the development of a new medicine – either for selection of patients or for assignment to treatment – the companion diagnostic test may significantly influence the overall benefit-risk ratio of this medicine as demonstrated during development.
- The quality and clinical utility of a companion diagnostic test may affect the safety of the medicinal product for which it is used.

Good (regulatory) management in this field will benefit the ‘personalised’ or ‘targeted’ healthcare in the future.

Full article: European Biotech News No 9 2013 – Authors; T. Ostler, D. Niese – regulanet™
Biotechnica 2013

The national thematic network for biotechnology, NTN Swiss Biotech, supported by the national funding agency, CTI (Commission for Technology and Innovation) made this exhibit possible. Eight projects are displayed at the Swiss Pavilion. The projects are co-funded by academic institutions and industry partners located in Switzerland. This type of innovative collaboration is a cornerstone of the Swiss value proposition.